β-Adrenoceptor blockers are widely used to reduce heart rate, the strongest predictor of mortality in cardiac patients, but are less effective in diabetic patients. This study aimed to determine the specific β1 - and β2 -adrenoceptor subtype contributions to chronotropic responses in type 2 diabetes in vivo, which are currently unknown.